Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entheon BiomedicalENTBF EV-to-OCF is -5.97 as of Aug. 12, 2026. Among 1,407 Biotechnology companies, Entheon Biomedical ranks better than 59.77% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Entheon Biomedical's Enterprise Value is $0.36 Mil.
Entheon Biomedical's Cash Flow from Operations for the trailing twelve months (TTM) ended in May. 2026 was $-0.06 Mil. Therefore, Entheon Biomedical's EV-to-OCF for today is -5.97.
The historical rank and industry rank for Entheon Biomedical's EV-to-OCF or its related term are showing as below:
ENTBF'
s EV-to-OCF Range Over the Past 10 Years
Min: -17.97 Med: -1.28 Max: 0.21
Current: -6.04
During the past 9 years, the highest EV-to-OCF of Entheon Biomedical was 0.21. The lowest was -17.97. And the median was -1.28.
ENTBF's EV-to-OCF is ranked better than 59.77% of 1407
companies
in the Biotechnology industry
Industry Median: -3.54
vs ENTBF: -6.04
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Entheon Biomedical's PE Ratio (TTM) for today is calculated as:
Entheon Biomedical's share price for today is $0.0041.
Entheon Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.015.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Entheon Biomedical EV-to-OCF Related Terms
Entheon Biomedical EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Entheon Biomedical's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Entheon Biomedical's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entheon Biomedical EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entheon Biomedical's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Entheon Biomedical's EV-to-OCF falls into.
Entheon Biomedical's current Enterprise Value is $0.36 Mil.
Entheon Biomedical's Cash Flow from Operations for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entheon Biomedical (ENTBF) has a EV-to-OCF of -5.97 as of Aug. 12, 2026. According to the industry distribution chart, Entheon Biomedical ranks #566 out of 1407 companies in the Biotechnology industry, placing it in the top 40.2%.
Is Entheon Biomedical's EV-to-OCF too high?
Entheon Biomedical's current EV-to-OCF is -5.97. Based on the distribution chart, Entheon Biomedical ranks #566 out of 1407 companies in the Biotechnology industry, which is above the industry midpoint.
How does Entheon Biomedical's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entheon Biomedical ranks #566 out of 1407 companies for EV-to-OCF. This puts Entheon Biomedical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Entheon Biomedical's current EV-to-OCF is -5.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entheon Biomedical stock overvalued right now?
Entheon Biomedical (ENTBF) has a current EV-to-OCF of -5.97. The current EV-to-OCF is -5.97. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Entheon Biomedical (ENTBF), the current EV-to-OCF is -5.97 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ENTBF has been successfully added to your 
